A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Metastatic Androgen-Independent Prostate Cancer
Study Status
Closed to Enrollment
Study Description
The purpose of this study is to find out how effective the experimental drug 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer (prostate cancer cells that do not depend on androgen for growth).
Patients will receive a single dose of 177Lu-J59 by IV infusion. One imaging study will be performed 1 week after treatment to confirm antibody targeting. Patients will be followed over the course of 12 weeks with close monitoring, including physician visits and bloodwork.
Disease Status and/or Stage
Metastatic, Hormone-Refractory Prostate Cancer
Sponsor
Weill Cornell Medical College
Key Eligibility
- Men age 18 and older
- Metastatic, hormone-refractory prostate cancer with evidence of progressive disease
- May have received prior chemotherapy
- Limited prior radiation therapy to the skeleton
- Adequate blood counts
- Additional eligiiblity criteria disussed when you contact the study team
Principal Investigator
Contact
- Gina Mileo, RN
- (212) 746-5430
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
